Working group on Pharmacokinetics and Population Pharmacokinetics of factor concentrates Alfonso Iorio, on behalf of the working group.

Slides:

Advertisements

Similar presentations

Vilnius, 29 June 2007 CIOMS Recommendations on Ethics in Medical Research The Eighth Global Forum on Bioethics in Research Gottfried Kreutz Dr. med., Dipl.-Chem.;

Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

The golden standard or fools gold Selective data, impact on safety Clinical trials on trial HAI Europe Open Seminar 2008 Neues Stadthaus, Berlin, 21 November.

UNM CTSC Mentored Career Development Scholars Program 6-Month Progress Report Template (Years 3+) Name Title Department or College.

© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.

 To facilitate the implementation of employment equity and the communication to employees of matters relating to employment equity and diversity.

Real-World Prophylaxis Experience: Perspectives from Clinical Practice Alfonso Iorio MD, PhD McMaster University Canada BeneF IX ® (nonacog alfa) is not.

AHRQ 2009 Annual Conference

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Special Topics in IND Regulation

Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates Xi M, Navarro-Ruan T, Mammen S, Blanchette.

Clinical Pharmacy Basma Y. Kentab MSc..

How to Write a Scientific Paper Hann-Chorng Kuo Department of Urology Buddhist Tzu Chi General Hospital.

Printed by Prevalence of Heparin in Samples Submitted for Lupus Anticoagulant Testing Nikhil A. Sangle MD FRCPath 1,3, George M.

11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.

Title of Project Your Name, Year Your Mentor’s Name Your mentor’s affiliations (e.g. Department, Location [UCD, Denver Health, etc.]) Other research team.

Working Group on Crime Statistics 9 June 2011 Point 3. Commission Activities ( Doc. CR/WG2011/1)

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD.

Clinical Pharmacy Part 2

SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.

Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Impact of E9 Addendum to Industry

Regular process for global reporting and assessment of the state of the marine environment, including socio-economic aspects Guidance for Authors.

Inhibitor development according to FVIII concentrate in PUPs: how to interpret current evidence? Alfonso Iorio Health Information Research Unit & Hamilton-Niagara.

Making Applications: Research Plan, Curriculum Vitae, List of Publications etc. Prof. Kaisa Miettinen

Inhibitor reporting standardization in previously treated patients Alfonso Iorio ISTH SSC – Factor VIII/IX Saturday June 20, 2015 Room 10:20 Room: 718.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

Non-adherence and its impact on treatment efficacy

WAPPS project (web accessible pharmacokinetics service)

H OW TO MEASURE PROGRESS IN THE PROVISION OF CARE FOR HEMOPHILIA Alfonso Iorio J Stonebraker, M Brooker, M Soucie. A workgroup of the Data and Demographics.

WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.

Slide 1 Federation des Experts Comptables Méditerranéens 4 th FCM Conference Capri, 3-4 May 2004 The Globalisation of Small and Medium-sized Enterprises.

FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.

With Co-Chairs: Dr Chris Barnes and Dr Simon McRae

Annual Report Constitution Public Audit Act Public Finance Management Act Other legislation Minister of Finance Establishment and operations National.

Risk factors for inhibitor development: any clinical role? Alfonso Iorio McMaster University Canada.

FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.

H ⊕ lger Schünemann, MD, PhD Professor and Chair, Dept. of Clinical Epidemiology & Biostatistics Professor of Medicine Michael Gent Chair in Healthcare.

Population-based PK in haemophilia A

LONDON BOROUGH OF MERTON: LOCAL INVOLVEMENT NETWORK (LINk) PUBLIC MEETING 8 February 2008 Richard Poxton Centre for Public Scrutiny National Team.

Course title: RESEARCH PLANNING AND REPORT WRITING Lecture 1 Introduction to postgraduate research.

CURRENT ADVERSE EVENTS REPORTING IN HEMOPHILIA

A capacity building programme for patient representatives

Managing Inhibitor Risk in both PUPs and PTPs

Support- IRDiRC Proposed Work Plan And Communication Strategy

Working Group on Pharmacokinetics and Population Pharmacokinetics

Copyright © 2017 American Academy of Pediatrics.

Connecting Pharmacokinetics and Phenotypes to Tailored Hemophilia Treatment 1. Pharmacokinetic approaches Professor Alfonso Iorio, MD, PhD, FRCPC.

Using pharmacokinetics to individualize hemophilia therapy

Alfonso Iorio, on behalf of the working group

Progress Report on the Patient Reported Outcomes Harmonization Team

Conflict of Interest Disclosure:

ICTMS Communicating Trial Results to participants

Exploring Personalized Prophylaxis in Hemophilia A

Author, Company and/or Logo Information

Conflict of Interest Disclosure (over the past 24 months)

Author, Company and/or Logo Information

Suzanne M. Sensabaugh, MS, MBA

Faculty Disclosure In accordance with the policy of the Cardiac Society of Australia and New Zealand the following presenter has indicated that they have.

CanMEDS Roles Covered X

Faculty Disclosure Slide Templates

Author, Company and/or Logo Information

Speaking on Behalf of ASME

CanMEDS Roles Covered X

We have no conflict of interests related to

　Form1-A　There is no state of conflict of interest requiring disclosure

Aparna Raychaudhuri, Ph. D

CanMEDS Roles Covered X

Presentation transcript:

Working group on Pharmacokinetics and Population Pharmacokinetics of factor concentrates Alfonso Iorio, on behalf of the working group

DISCLOSURES Financial conflicts of interests – McMaster University has received funds for research and service agreements from Bayer, Baxalta, Biogen, NovoNordisk, Octapharma, and Pfizer. Non-financial (intellectual) conflicts – PI for the WAPPS project ( No mention of unlicensed products

WORKING GROUP Core members – A Iorio, V Blanchette, P Collins, K Fischer, J Blatny, E Neufeld Additional members – D Lillicrap, D Hart, M Makris PK and PopPK consultants – A Edginton, S Ito

Previous SSC Communications The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Morfini M, Lee M, Messori A. Thromb Haemost Sep 2;66(3):384-6.

Previous SSC Communications Scientific and Standardization Committee Communication The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis M. Lee, M. Morfini, S. Schulman, J. Ingerslev and the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH Posted on the ISTH SSC on March 21, 2001

Previous SSC Communications … the approaches recommended here are primarily intended for clinical trials of factor concentrates that are being compared to other, similar preparations. … studies on individual patients for diagnostic or therapeutic purposes may not necessarily be relevant to what is discussed here.

Previous SSC Communications

AIMS: Primary PK and PopPK estimates of factor concentrates: – Reporting – Interpretation – Assessment in clinical practice – Study design for “real world/PM” PopPK assessment

AIMS: Secondary PK and PopPK estimation: – During registration phase – To compare different molecules – Choice of time points – ….

PROCESS How (and whether) to best involve: – Pharmaceutical companies PK/PopPK experts – FDA / EMA PK/PopPK experts – Authors of PK/PopPK published papers – Patient representatives

PROGRESS 2 conference calls 1 panel survey Bi-monthly conference calls Review of the existing literature Review of regulators guidance Draft recommendations on primary goals

Questions time Thank you for attention Slides posted on: